These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26683302)

  • 1. Effect of Urate-Lowering Therapy on All-Cause and Cardiovascular Mortality in Hyperuricemic Patients without Gout: A Case-Matched Cohort Study.
    Chen JH; Lan JL; Cheng CF; Liang WM; Lin HY; Tsay GJ; Yeh WT; Pan WH
    PLoS One; 2015; 10(12):e0145193. PubMed ID: 26683302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Urate-lowering Therapy on the Risk of Cardiovascular Disease and All-cause Mortality in Patients with Gout: A Case-matched Cohort Study.
    Chen JH; Lan JL; Cheng CF; Liang WM; Lin HY; Tsay GJ; Yeh WT; Pan WH
    J Rheumatol; 2015 Sep; 42(9):1694-701. PubMed ID: 26077411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urate-lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink.
    Kiddle SJ; Sundell KA; Perl S; Nolan S; Bjursell M
    Clin Cardiol; 2024 Jun; 47(6):e24297. PubMed ID: 38873862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout.
    Yen FS; Hsu CC; Li HL; Wei JC; Hwu CM
    PLoS One; 2020; 15(6):e0234909. PubMed ID: 32574194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study.
    Larsen KS; Pottegård A; Lindegaard HM; Hallas J
    Am J Med; 2016 Mar; 129(3):299-306.e2. PubMed ID: 26589484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between urate-lowering therapy and cardiovascular events in patients with asymptomatic hyperuricemia.
    Hashimoto H; Takeuchi M; Kawakami K
    Clin Rheumatol; 2023 Nov; 42(11):3075-3082. PubMed ID: 37486577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.
    Levy GD; Rashid N; Niu F; Cheetham TC
    J Rheumatol; 2014 May; 41(5):955-62. PubMed ID: 24692523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of allopurinol use on urate concentration and cardiovascular outcome.
    Wei L; Mackenzie IS; Chen Y; Struthers AD; MacDonald TM
    Br J Clin Pharmacol; 2011 Apr; 71(4):600-7. PubMed ID: 21395653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Safety of Urate Lowering Therapies.
    Kang EH; Kim SC
    Curr Rheumatol Rep; 2019 Jul; 21(9):48. PubMed ID: 31342190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
    Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
    Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
    Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
    Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Urate Lowering Therapy on Renal Disease Progression in Hyperuricemic Patients with Chronic Kidney Disease.
    Kim Y; Shin S; Kim K; Choi S; Lee K
    J Rheumatol; 2015 Nov; 42(11):2143-8. PubMed ID: 26428209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is urate crystal precipitation a predictor of cardiovascular risk in hyperuricemic patients? A Danish cohort study.
    Larsen KS; Pottegård A; Lindegaard H; Hallas J
    Arthritis Res Ther; 2015 Oct; 17():304. PubMed ID: 26515421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.
    Kim SC; Schneeweiss S; Choudhry N; Liu J; Glynn RJ; Solomon DH
    Am J Med; 2015 Jun; 128(6):653.e7-653.e16. PubMed ID: 25660249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.
    Janssen CA; Oude Voshaar MAH; Vonkeman HE; Krol M; van de Laar MAFJ
    Clin Rheumatol; 2018 Aug; 37(8):2291-2296. PubMed ID: 29721712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout.
    Yen FS; Wei JC; Chang CL; Yang CC; Hsu CC; Hwu CM
    Int J Med Sci; 2021; 18(12):2599-2606. PubMed ID: 34104091
    [No Abstract]   [Full Text] [Related]  

  • 17. Factors associated with initiation and persistence of urate-lowering therapy.
    Dehlin M; Ekström EH; Petzold M; Strömberg U; Telg G; Jacobsson LT
    Arthritis Res Ther; 2017 Jan; 19(1):6. PubMed ID: 28095891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan.
    Hakoda M; Kasagi F
    Mod Rheumatol; 2019 Sep; 29(5):880-884. PubMed ID: 30175646
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.
    Hosoya T; Sasaki T; Hashimoto H; Sakamoto R; Ohashi T
    J Clin Pharm Ther; 2016 Jun; 41(3):298-305. PubMed ID: 27079434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urate-lowering therapy exerts protective effects against hypertension development in patients with gout.
    Lin KH; Yen FS; Li HL; Wei JC; Hsu CC; Yang CC; Hwu CM
    J Hum Hypertens; 2021 Apr; 35(4):351-359. PubMed ID: 32366929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.